On January 14, 2019. CanSino Biologics Inc., (CanSinoBIO) a China-based vaccine company focusing on the development and manufacturing of preventive and therapeutic vaccines announced that the company signed a supply agreement with VaxYnethic (Siena, Italy) for the development and production of conjugated vaccines for human use.
Under the agreement, CanSinoBIO will develop, manufacture and supply polysaccharides and carrier proteins to VaxYnethic for the development of conjugate vaccines for global markets. All products delivered by CanSinoBIO will meet international quality standards and will be manufactured at CanSino facility in Tianjin in full compliance with US and EU GMP Regulations.
Dr. Xuefeng Yu, Chairman of the Board and CEO of CanSino Biologics Inc. said: “This is a significant development for CanSinoBIO. It further demonstrates our strong capabilities in vaccines development and manufacturing in compliance with global quality standards. It also brings more partnership opportunities globally for CanSinoBio in the future. We are very pleased to collaborate with one of the world’s best biopharmaceutical group.”
Massimo Porro, CEO of VaxYnethic, added:
“This is a great opportunity for us to work with CanSino Biologics Inc., one of the best vaccine companies in China. It represents the result of the continuous evolution in biotechnology which has progressed through time in complementary sectors within the biopharmaceutical field.”
CanSinoBIO (www.cansinotech.com) is a fully integrated vaccine company dedicated to develop, manufacture and commercialize high quality, innovative vaccines. Founded in the Tianjin Economic and Technological Development Area (TEDA) in 2009, CanSinoBIO’s founders formed a superb team of scientists and managers who had previously held senior management and technical positions at many of the world’s leading pharmaceutical companies. CanSinoBIO has established a robust vaccine pipeline and multiple platform technologies including the viral vector based vaccine development platform.
VaxYnethic, a joint venture between Menarini Group and BiosYnth, is engaged in a medium to long term research and industrial project on an innovative technological platform for the production of biopharmaceuticals. The objective of the company is to work on a new technology developed by BiosYnth, a pioneer Company in the field of glycoconjugate vaccines, which will allow researchers to expedite the production processes of biopharmaceuticals, as well as co-operate with other market players in order to reduce the manufacturing time for vaccines and satisfy the ever growing demand on a worldwide scale.
About the Menarini Group
The Menarini Pharmaceutical Group, with headquarters in Florence, is currently present in over 130 countries worldwide with 17,000 employees and, with a turnover of 3.6 billion euro, is the 13th company out of 5,345 in Europe and the 35th out 21,587 in the world (source Quintiles IMS). With 7 centres for Research & Development, Menarini’s products are present in the most important treatment areas, including cardiologic, gastroenterologic, pneumologic, infectious diseases, diabetic and anti-inflammatory/analgesic products. Pharmaceutical production is carried out in the Group's 16 manufacturing plants located in Italy and abroad, which produce and distribute over 580 million packets of product a year. Menarini's pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients throughout the world.
Copyright © ( 2017) CanSino Biologics Inc
For the record: 津ICP备14006666号-2